Facilitated PCI: No Benefit in FINESSE

You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.

C. Michael Gibson, M.S., M.D. September 3rd 2007

Vienna, Austria: The FINESSE Trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events trial) has failed to demonstrate a significant advantage of pre-treating patients with a lytic prior to primary angioplasty. This trial adds to data such as that reported in ASSENT 4 which demonstrated no benefit to lytic administration prior to primary PCI.

Design

FINESSE evaluated three strategies in ST elevation (STEMI) patients undergoing PCI:

1. Pre-PCI abciximab plus half-dose thrombolytic (reteplase)(n=828)
2. Pre-PCI abciximab alone (n=818)
3. Pre-PCI placebo with abciximab during the procedure (n=806).

The trial was double blind. The aspirin dosing was 81 mg to 325 mg orally or 250 mg to 500 mg IV, and thienopyridines were administered at the discretion of the investigator. Heparin dosing was reduced to 40 U/kg bolus with a maximum of 3000 U).

GPIIbIIIa Inhbition Used to Offset Platelet Aggregation with a Lytic

Abciximab was continued for 12 hours after the procedure. The use of abciximab in all patients in the trial (with and without a lytic) is in contrast to ASSENT 4 where the minority of patients (about 10%) received a GP IIbIIIa inhibitor. The poor outcomes (including a higher rate of reinfarction) observed in ASSENT 4 were attributed in part to insufficient antiplatelet therapy to counter the platelet activation accompanying lytic administration. It was speculated that the more aggressive GP IIbIIIa regimen in FINESSE would overcome this problem.

Fairly Long Door To Balloon Times Allow Better Testing of the Hypothesis

Door to balloon times were 120 minutes in the 60% of patients who were randomized at a hospital with on site PCI and 155 minutes in the 40% of patients who were transferred from a spoke hospital into a hub hospital for a PCI. These delays are greater than that observed in ASSENT 4 where the overall delay was only 104 minutes. Thus, given this longer delay, this trial was in a better position than ASSENT 4 to test the hypothesis that in patients in whom a delay is anticipated, pre-treatment with a lytic would improve outcomes. The 155 minute delay among transfer patients is not that different than the current 170 minute delay in the US if a transfer is involved thus allowing reasonable testing of the benefit involved in administering a lytic prior to transfer.

Double the Patency Observed with a Lytic on Board

Not surprsingly, more patients in the pre-PCI reteplase+abciximab arm had an open artery prior to PCI (61%) compared with either the pre-PCI abciximab arm (26%; p < 0.001) or the pre-PCI placebo plus abciximab during the procedure (25%; p < 0.001). Another marker of pre-PCI epicardial and myocardial reperfusion, complete ST segment resolution (>70% ST resolution by 60-90 minutes) was also more common in the pre-PCI reteplase + abciximab arm (44%) than either the pre-PCI abciximab arm (33%; p = 0.013) or the pre-PCI placebo plus abciximab during the case arm (31%; p = 0.003).

Improved Pre-PCI Patency with Reteplase Fails to Improve Clinical Outcomes

Despite more than doubling pre-PCI patency, pre-PCI reteplase + abciximab was not associated with an improvement in the primary endpoint of death, cardiogenic shock, heart failure, or resuscitated ventricular fibrillation by 90 days. The primary ednpoint was observed in 9.8% of the pre-PCI reteplase + abciximab patients, 10.5% of the pre-PCI abciximab patients, vs 10.7% of the pre-PCI placebo + abciximab administered during the procedure; p = NS).

No Difference in Individual Components of the Primary Endpoint

No difference was observed in mortality (5.2%, 5.5%, 4.5%, respectively), heart failure (1.9%, 2.9%, 2.2%), cardiogenic shock (5.3%, 4.8%, 6.8%), or ventricular fibrillation (0.6%, 0.2%, 0.4%).

Pre-PCI Lytic was Associated with Increased Bleeding

Not surprisingly, the combination of TIMI major or minor bleeding was higher in the pre-PCI reteplase + abciximab arm (14.5%) vs the pre-PCI abciximab arm (10.1%; p = 0.008) or the pre-PCI placebo plus abciximab during the case arm (6.9%; p < 0.001). Intracranial hemorrhage occurred in 0.6% of the combination facilitated PCI arm but none of the abciximab facilitated PCI arm and in 0.1% of the primary PCI alone group (p=NS).

Conclusions

While pre-PCI reteplase did more than double pre-PCI patency, this was not associated with an improvement in the primary endpoint or clinical endpoints of LV function, but its administration was associated with an increased risk of bleeding.

The reason for this lack of association between improved pre-PCI patency and improved clinical outcomes is not clear. It could be speculated that the arteries were closed too long for early opening to be of benefit. Early opening of an artery that ends in a swollen and edematous capillary bed is likely to be of little use. In ASSENT 4, pre-PCI lysis tended to perform better among patients who presented early and had non-organized clot that was still susceptible to lysis. Thus, the results stratified by duration of symptoms will be of ongoing interest.

Other hypotheses to explain the lack of benefit of lysis include the possibility that pre-PCI lysis may enhance reperfusion injury or that it may be associated with intra-myocardial hemorrhage.

One future trial, the STREAM trial, is planned to again evaluate pre-PCI lysis.

TNK administered via the intracoronary route is also being evaluated to improve microcirculatory function following primary PCI.

WikiDoc Help Menu Quick Start.. Get Started Here! How to Login How to Search Pages How to Start a New Page How to Edit a Page Cheat Sheet Editing basics Learning Basic Formatting How to make Links in WikiDoc & to External Sites How to Make Lists How to Ignoring Formatting Adding References or Footnotes to Articles Tracking Changes You Have Made How to Put an Article Into a Category When Multiple Topics Should Go To The Same Page (MI, Acute MI, AMI) Using Redirection Advanced editing How to Make Tables How to Insert Images and Other Media How to Add Video Help:How to Make Columns Web Colors How To Make Templates How to Move Pages Inserting Dynamic Dates and Times Inserting WikiDoc Statistics Editing the Table of Contents Communicating your edits Let others know what you changed: The importance of Edit Summaries Minor Edits Edit Conflicts Help Videos You Can Watch Getting Started Video

Acknowledgement and Attribution Regarding Sources of Content

Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .